Table 5. Characteristics of the Nurr1 agonist 37.
|
|
|---|---|
| EC50 (Nurr1) a | 0.06±0.02 μM |
| efficacy a | 1.9±0.1-fold |
| Kd (Nurr1) b | 0.12 μM |
| EC50 (NBRE) a | 0.07±0.02 μM |
| EC50 (NurRE) a | 0.027±0.008 μM |
| EC50 (DR5) a | 0.014±0.006 μM |
| EC50 (Nur77) a | 0.04±0.01 μM |
| EC50 (NOR1) a | 0.07±0.03 μM |
| selectivity (NR1-3) a | > 50-fold |
| toxicity c | > 10 μM |
| logP d | 2.83±0.02 |
| aq. sol. e | 4.4 mg/L (13.8 μM) |
| microsomal half-life | > 4 h |
| LE f | 0.43 |
| LLE e | 4.4 |
a
From reporter gene assay; data are the mean±S.E.M., n≥3.
b
From ITC.
c
From a multiplex toxicity assay monitoring confluence, metabolic activity, necrosis and apoptosis in HEK293T and COS-7 cells.
d
The logP was experimentally determined following the OECD test guideline #117.
e
Refers to thermodynamic solubility.
f
Ligand efficiency (LE) and lipophilic ligand efficiency (LLE) were calculated according to 38.